Another drug that has obtained positive results is tideglusib, which has been tested in a transgenic mouse model of AD, showing reduced tau phosphorylation and reduced Aβ peptide accumulation, preventing neuronal death and maintaining cognitive function. Here, MAPT is linked to Alzheimer disease.